PAA 0.00% 17.5¢ pharmaust limited

Amylyx class action Relyvrio, page-12

  1. 8,527 Posts.
    lightbulb Created with Sketch. 814
    It seems Riluzole is not so effective as increasing median survival by up to 19 months.

    There is an article online entitled: "Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)."

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055506/#:~:text=The%20results%20indicate%20that%20riluzole,longer%20than%20participants%20taking%20placebo.

    "Riluzole 100 mg daily is reasonably safe and probably prolongs median survival by about two to three months in patients with amyotrophic lateral sclerosis."

    Admittedly that was published back in 2012, so have there been more recent studies on the properties of Riluzole?
 
watchlist Created with Sketch. Add PAA (ASX) to my watchlist
(20min delay)
Last
17.5¢
Change
0.000(0.00%)
Mkt cap ! $85.12M
Open High Low Value Volume
18.0¢ 18.0¢ 17.0¢ $141.2K 801.7K

Buyers (Bids)

No. Vol. Price($)
11 537419 17.0¢
 

Sellers (Offers)

Price($) Vol. No.
18.0¢ 140000 3
View Market Depth
Last trade - 16.10pm 06/09/2024 (20 minute delay) ?
PAA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.